Evidence map›Paper›PMID 37949468›Full record

ArticleAnnals of the rheumatic diseases2024

Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO).

Susan Bridgewater, Mwidimi Ndosi, Jill Dawson, Pamela Richards, Christine Silverthorne, Emma Dures, Susan M Goodman, Catherine Hill, Sarah L Mackie, Joanna C Robson

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06314451 (Cross-condition Validation of the Patient Reported Outcome Measure for Patients Receiving Glucocorticoids), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06314451 unknown statusnot on this map

Cross-condition Validation of the Patient Reported Outcome Measure for Patients Receiving Glucocorticoids (the Steroid PRO)

TypeobservationalSponsorUniversity of the West of EnglandRan2022 to 2024Enrolled60ConditionsInflammatory Disease, Immune System Disorder, Gastrointestinal Diseases, Dermatologic DiseaseArmsCognitive Interview
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Susan Bridgewater *School of Health and Social Wellbeing, University of the West of England, Bristol, UK.
Mwidimi Ndosi *School of Health and Social Wellbeing, University of the West of England, Bristol, UK.ORCID http://orcid.org/0000-0002-7764-3173
Jill DawsonNuffield Department of Population Health, University of Oxford, Oxford, UK.
Pamela RichardsSchool of Health and Social Wellbeing, University of the West of England, Bristol, UK.
Christine SilverthorneSchool of Health and Social Wellbeing, University of the West of England, Bristol, UK.
Emma DuresSchool of Health and Social Wellbeing, University of the West of England, Bristol, UK.
Susan M GoodmanRheumatology Department, Hospital for Special Surgery, New York, New York, USA.
Catherine HillRheumatology Department, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Sarah L MackieInstitute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Joanna C RobsonSchool of Health and Social Wellbeing, University of the West of England, Bristol, UK Jo.Robson@uwe.ac.uk.ORCID http://orcid.org/0000-0002-7939-5978
University of the West of England · GBHospital for Special Surgery · USQueen Elizabeth Hospital · AUUniversity of Leeds · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGlucocorticoids used in the treatment of inflammatory rheumatic conditions can impact on health-related quality of life. An underpinning qualitative study developed a long-list of candidate items for a treatment-specific patient-reported outcome (PRO) measure. The objective of this paper is to determine scale structure and psychometric properties of the Steroid PRO.

methodsA cross-sectional survey of adults from the UK, USA, Australia and New Zealand, taking glucocorticoids for a rheumatic disease. Initial survey collected demographics, clinical information, 40 Steroid PRO candidate items and EuroQol-5 Dimensions- 5 levels (EQ-5D-5L). Follow-up, 3-5 days later, collected Steroid PRO candidate items and a condition-change ('transition') question. Analysis included Rasch measurement model, exploratory factor analysis (EFA), and hypothesis testing for discriminative validity, convergence validity and test-retest reliability.

resultsTotal responses 946: UK n=743 (79%); USA n=139 (15%); Australia/New Zealand n=64 (7%); mean age 57.6 (SD=13.6); 833 (88%) women. Participants with inflammatory arthritis n=197 (21%), connective tissue disease and/or vasculitis n=402 (42%), giant cell arteritis and/or polymyalgia rheumatica n=347 (37%). Twenty-five items were removed due to lack of fit to Rasch model. Of the remaining items, EFA suggested four subscales: Social impact (4 items); Impact on appearance (3 items); Psychological impact (5 items); Treatment concerns (3 items). Rasch modelling supported a four-subscale structure and total score, confirming construct validity and reliability. Hypothesis testing confirmed discriminant and convergence validity. Intraclass correlation coefficient (total score) was 0.809 demonstrating excellent (test-retest) reliability.

conclusionsThe Steroid PRO is a 15-item, valid and reliable scale for measuring the impact of glucocorticoid therapy in people with rheumatic diseases.

Indexed as

Quality of LifeRheumatic DiseasesAdultCross-Sectional StudiesFemaleGlucocorticoidsHumansMaleMiddle AgedPatient Reported Outcome MeasuresPsychometricsReproducibility of ResultsSteroidsSurveys and QuestionnairesGlucocorticoidsSteroidsArthritis, RheumatoidConnective Tissue DiseasesGlucocorticoidsPatient Reported Outcome MeasuresSystemic vasculitis

Identifiers

PMID37949468
PMCPMC10894813
OpenAlexW4388563716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.